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Abstract 
Background: Vagus nerve stimulation (VNS) can induce a sleep apnea syndrome (SAS), 
which in turn can worsen seizure control and represents a cardiovascular risk factor. 
Epidemiology of VNS-induced SAS has received little attention to date. The purpose of this 
study is to estimate the VNS-induced SAS prevalence and to explore clinical variables 
potentially correlating with its development.  
Methods: We analyzed the computerized medical records of 18 consecutive adults treated for 
refractory epilepsy with VNS, implanted between May 2008 and October 2015. Patients 
underwent polygraphy or polysomnography before and after VNS implantation. Between 
patients with and without SAS, we compared variables related to epilepsy type and device 
parameters.  
Results: Two patients had SAS and were treated before implantation; one improved after 
VNS, the other worsened. Four other patients developed SAS after VNS: induced/aggravated 
SAS occurred in 5/18 patients (prevalence: 27.8%). Only 2 of them had symptoms: one 
complained of important snoring, the other reported seizure worsening. All 5 patients were 
successfully treated by combinations of cPAP, positional therapy, or VNS parameters 
modification. There was no statistically significant difference between potential predictors.   
Conclusion: Despite the relatively modest clinical impact on epilepsy, in view of the 
associated cardiovascular risk factor development, easy treatment, and the relatively high 
SAS prevalence, routine screening for SAS before and after VNS implantation may represent 
a reasonable practice. 
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1.Introduction 
 
Vagus nerve stimulation (VNS) is a palliative therapy for refractory epilepsy; it is used since 
more than 20 years and is regarded as safe, well tolerated and effective [1-5]. A seminal study 
about the effect of VNS on sleep [6] analyzed polysomnographies (PSG) of four patients with 
VNS before and after treatment, showing that the apnea-hypopnea index (AHI) was 
significantly higher with activated VNS; several subsequent observations found comparable 
results [7-10]. VNS seem to increase both respiratory effort and airways obstruction during its 
activation [6,7,9-13]. Both peripheral and central mechanisms represent possible explanations 
for changes in respiratory patterns. The former would be triggered by stimulation and 
subsequent narrowing of the upper airways musculature [6,7,12,14]. Since the vagus nerve 
has projections to the brainstem respiratory control centers [6,7,12,14], a central inhibition of 
respiratory drive could also be observed.  
 
Even if changes in respiratory patterns are found in many patients, they do not seem clinically 
relevant in most. While the majority of studied patients shows changes in respiratory patterns 
(34-100%), only 0-33% develop SAS [7,12,13,15]. To date, however, the prevalence of SAS 
in patients with VNS remains largely unknown, due to the fact that the aforementioned 
studies included relatively small groups of patients selected from a sleep medicine angle, who 
are not necessarily representative of the whole population of patients with epilepsy implanted 
with VNS. Nevertheless, VNS related SAS seems to be frequent enough that sleep study 
screening before implantation is considered [8,9,12,13,16,17]. Screening after the 
implantation could be also important, in as much as VNS increases wakefulness [18], which 
could mask one of the cardinal symptoms of SAS, daytime somnolence [6,19,20].  
 
While lacking an evidence-based approach, many treatment options have been described for 
patients with VNS related SAS: continuous positive airway pressure (cPAP) 
[8,9,13,14,16,17,21]; positional therapy [8,9]; changes in stimulator settings (especially  
increasing OFF time or decreasing stimulation frequency) [6,8,16,17,22]. It has been 
suggested that VNS parameters modifications might further enhance the cPAP impact [14]. In 
severe cases, VNS deactivation at night has been mentioned [8,16,17]. Treating SAS seems 
important not only for the quality of life, but also because sleep disruption can increase 
seizure frequency [6,8,17], on top of representing an independent cardiovascular risk factor 
[19,23]. 
 
To summarize, a link between the VNS and sleep respiratory disorders is described but the 
prevalence of this side effect is unknown. Clinical variables potentially associated with it have 
not been clearly elucidated to this day, with only one recent study postulating left vocal cord 
abduction as a predisposing factor [17].  
 
2.Methods 
 
This is a retrospective cohort study  assessing the prevalence of VNS-induced SAS, and 
exploring potential clinical variables correlating with its development. The study was 
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approved by our ethics committee.  
 
We analyzed the computerized medical records of consecutive adults (>18 years old) 
implanted with VNS for refractory epilepsy at our center between May 2008 and October 
2015; follow-up extended until May 2017.  Sleep recordings took place in our sleep center 
(PSG) or at home (PG), in accordance with the American Academy of Sleep Medicine's 2007 
recommendations [24]. Apnea was defined as a decrease of at least 90% of airflow from 
baseline, lasting 10 s or longer, while hypopnoeas were scored according to the 2012 
American Academy of Sleep Medicine criteria (≥30% decrease of airflow lasting at least 10 s, 
associated with either arousal or a ≥3% O2 saturation decrease) [25]. All studies but one were 
conducted at the sleep center of the CHUV and interpreted by AOR, a sleep certified 
neurologist. Most studies were ambulatory polygraphies, chosen as they are more convenient 
than polysomnographies both for patients and reimbursement, while retaining comparable 
sensitivity in SAS diagnosis [26,27]. All patients underwent a sleep study before implantation 
to screen for SAS, as this would have needed specific treatment. They also underwent a 
control sleep study after implantation. The mean number of apnoeas and hypopnoeas per hour 
of sleep (apnoea-hypopnoea index [AHI]) was calculated. SAS was defined after [16] (mild: 
AHI=5-10/h, moderated: AHI=10-15/h; severe if AHI≥15). We stratified the cohort in two 
groups: patients who worsened already existing SAS or developed it after implantation, 
patients without SAS worsening or development.  
 
We compared several potential explanatory variables related to SAS development between 
the two groups:  demographics, being overweight (defined as a BMI>25), history of arterial 
hypertension or diabetes, variables related to epilepsy diagnosis (main seizures type -focal or 
generalized-, percentage of VNS related decrease in seizures frequency, medication -presence 
of valproate, VPA), VNS parameters (current intensity, pulse frequency, duration, and ON 
and OFF times). We also compared the reported magnet efficacy (defined as an effect in at 
least 30% of seizures in terms of shortening of the episode or of the postictal state) and a 
subjective significant increase in vigilance (reported by the patient or relatives/caregivers).  
 
Given the small groups of patients, Fisher’s exact tests were used to analyze dichotomous 
variables, and Mann-Whitney U-tests for continuous variables, using two-tailed approaches. 
We used the online application Socscistatistics [28] to perform the tests, and considered p-
values <0.05 to be statistically significant. Correction for multiple comparisons was not 
performed in view of the exploratory character of the study.  
3.Results 
 
In the study period, 19 adult patients received VNS at CHUV, of whom one died of a 
probable SUDEP after eight months; due to lack of information regarding sleep quality, we 
excluded him from the study. We therefore analyzed 18 patients. The main clinical variables 
for each patient are summarized in Table 1, types of sleep studies performed and the observed 
AHI are summarized in Table 2. All patients had a sleep study before implantation: two 
showed SAS (patient 6 was treated with positional therapy, patient 9 with cPAP); a follow-up 
sleep study occurred after a median latency of 36 months (range: 6 months to 7 years) in 16 
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patients; in two subjects with severe cognitive impairment relatives refused to perform a 
follow-up study. These two patients showed no symptom suggesting SAS (increased 
somnolence, snoring, xerostomia), nor seizure worsening and were attributed to the group 
with no SAS. Four subjects (patients 1,4,13 and 15) developed SAS de novo and patient 9 
with cPAP showed worsened AHI. The rate of VNS-induced or aggravated SAS was thus 
27.8%. The majority of respiratory events were hypopneas, mostly of obstructive nature, 
although a central component was observed in up to 25% of them (details not shown).  
  
The SAS of patient 1, whose husband complained about new-onset snoring and apneas, 
resolved by changing the device parameters: intensity and pulse frequency were reduced and 
a high duty cycle mode was activated. She underwent two follow-up sleep studies: the first 
with parameters unchanged showed an AHI at 12.7/h, the second one, with modified 
parameters, an AHI at 0/h. Patient 4 was not treated for SAS since the latter had no clinical 
impact. Patient 9 had already cPAP before implantation and continued it, he remained 
asymptomatic. Patient 13 had an increased daytime seizure frequency after VNS, possibly 
promoted by SAS; she improved regarding both seizures and SAS  by decreasing current 
intensity from 1.75 mA to 1.25 mA. Patient 15 had no complaint related to SAS, nevertheless 
OFF-time was increased from 3 to 5 minutes.  
 
As exposed in Table 3, there was no significant difference between patients with and without 
VNS induced/aggravated SAS on any collected variable, except a trend for greater VNS 
intensity in the SAS group.  
4.Discussion  
 
To the best of our knowledge, our study is the first to estimate the rate of VNS-induced SAS 
in a non-selected adult population, and to explore clinical variables potentially correlated to 
the development of a SAS after VNS implantation. The main findings were that VNS induced 
or aggravated SAS in 27.8% of patients; we did not find any variable significantly predicting 
the risk of VNS-induced SAS.    
Our results confirm the link between VNS and SAS, and therefore seem to justify a routine 
post-implant screening. The prevalence of SAS before VNS implantation in our cohort (2/18 
patients, 11%) admittedly appears somewhat lower than that reported in a recent population-
based study conducted with home polysomnography in our geographic area [29]. This may be 
related to a younger age of our patients and lower prevalence of SAS risk factors, such as high 
blood pressure, diabetes, and obesity, as compared to the aforementioned cohort. It seems 
unlikely that the methods used to detect SAS in our cohort underestimated its prevalence [26]. 
This might thus suggest that established risk factors for sleep apnea outside a VNS context, 
such as male gender, age, or metabolic syndrome [29-32] may not directly apply for VNS-
induced SAS. These observations support the idea that the still unclear pathophysiologic 
mechanisms of VNS-induced SAS are somewhat different from those causing SAS in subjects 
with no VNS or epilepsy.  
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We noticed that only one out of the five patients who developed SAS had concomitant  
increased seizures frequency. Nevertheless, we feel that screening for SAS in this particular 
population remains warranted, in as much as SAS is unlikely to remit spontaneously over 
time if VNS is pursued, and it represents an important cardiovascular risk factor [19,23]; for example, SAS treatment in an acute stroke setting may enhance functional recovery [33, 34]. Furthermore, the potential beneficial role of modifying SAS beyond vascular pathologies has been recently suggested , as it appears to be related to cognitive impairment [35]. 
 
Only higher stimulation intensity might possibly have an impact on SAS development, but 
requires confirmation in larger studies. This observation appears logical, since decreasing the 
intensity of stimulation are known to improve SAS. Concerning treatment, all the three 
patients whose VNS parameters were changed to treat SAS had their condition improved: 
increasing OFF time and reducing stimulation intensity seem effective [22].  
 
The present study confirms previously described information: respiratory events were more 
frequently obstructive than central [6,7,13]; furthermore 4/5 of our patients with VNS-
induced SAS reported increased vigilance as a favorable effect [18], underscoring that 
somnolence may be masked by VNS. 
 
We acknowledge that the study is limited by the small number of patients, which hampers its 
statistical power. Conversely, the fact that the population was non-selected by sleep criteria 
represents a strength in our view. Estimations of VNS effect on seizures and vigilance relied 
on reporting by patients and relatives and not on objective measures. This study was not 
designed to assess the type of SAS induced by VNS. As previously mentioned, PG and PSG 
should have comparable sensitivity in SAS diagnosis [26,27]. A further limitation is that two 
of our patients did not undergo any control sleep study after implantation, which could have 
led to underestimate the true rate of VNS-induced SAS. Further studies with larger cohorts 
seem necessary to shed further light on potential risk factors for developing SAS in this 
clinical setting.   
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Table 1: Clinical characteristics of all patients  
N°- 
Age-
Gender 
Epilepsy type Etiology % Reduction 
of seizures with 
VNS  
Parameters of VNS 
device (at time of the 
sleep study)  
 Medication   
1. 50-F Focal  Adult Rasmussen 
Encephalitis 
>75% 2.5 mA, 30 Hz, 250 
μs, 30 sec on, 05 mn 
off 
 LTG, PGB, LEV, 
CLZ 
* 
2. 34-F Focal/ 
generalized 
Ring 20 chromosome 0% 0.5 mA, 20 Hz, 250 
μs, 30 sec on, 5 mn 
off 
 OXC, CLZ  
3. 27-M Generalized  Dravet syndrome >75% 2.25 mA, 20 Hz, 250 
μs, 30 sec on, 5 mn 
off 
 PHT, VPA, LEV, 
CLZ 
 
4. 31-F Focal Unknowm >75% 2 mA, 20 Hz, 250 μs, 
21 sec on, 0.8 mn off 
 LTG, FBM, PGB * 
5. 39-M Generalized  Unknowm >50% 1.75 mA, 20 Hz, 250 
μs, 30 sec on, 5 mn 
off 
 VPA, LEV, LTG, 
CLZ 
 
6. 37-M Focal Polymicrogyria 
0%, shorter 
2.25 mA, 30 Hz, 250 
μs, 30 sec on, 1.8 mn 
off 
 LTG, VPA,
CLBZ 
 
7. 52-F Focal Hippocampus sclerosis 0%  2 mA, 20 Hz, 250 μs, 
30 sec on, 1.8 mn off 
 LTG, TPM  
8. 52-M Focal Perinatal hypoxia 
0%, shorter 
1.75 mA, 20 Hz, 250 
μs, 30 sec on, 5 mn 
off 
 LEV, PGB  
9. 26-M Focal Focal cortical 
dysplasia 
>90% 2 mA, 20 Hz, 250 μs, 
7 sec on, 0.3 mn off 
 PHT, OXC, RTG, 
CLZ 
* 
10. 35-F Focal Hippocampus sclerosis 50%, shorter 1.75 mA, 20 Hz, 250 
μs, 30 sec on, 5 mn 
off 
 CBZ, TPM, PGB  
11. 28-F Focal CDKL5 >70%, shorter  1.5 mA, 20 Hz, 250 
μs, 30 sec on, 5 mn 
off 
 LTG, VPA, 
CLBZ 
 
12. 31-M Generalized  Unknown >90% 1.5 mA, 20 Hz, 250 
μs, 30 sec on, 5 mn 
off 
 VPA, RUF, ZNS  
13. 26-F Focal  Perinatal hypoxia 50% 1.75 mA, 20 Hz, 250 
μs, 30 sec on, 1.8 mn 
off 
 OXC, LTG, LEV * 
14. 25-M Focal/ 
generalized 
Unknown >50% 1.75 mA, 20 Hz, 250 
μs, 30 sec on, 1.1 mn 
off 
 TPM, OXC, 
RUF, CLZ 
 
15. 34-M Generalized Unknown >50% 2 mA, 20 Hz, 250 μs, 
30 sec on, 3 mn off 
 PB, RUF, CLBZ * 
16. 25-M Generalized Unknown >90% 1.25 mA, 20 Hz, 250 
μs, 30 sec on, 5 mn 
off 
 LTG, TPM, VPA  
17. 23-M Focal Focal cortical 
dysplasia  
>75% 1.5 mA, 30 Hz, 250 
μs, 30 sec on, 5 mn 
off 
 LEV, CBZ, TPM, 
PER 
 
18. 22-M Generalized  Unknwon  >90% 1.25 mA, 20 Hz, 250 
μs, 30 sec on, 1.1 mn 
off 
 VPA, OXC, SUL, 
CLZ 
 
*Patients 1, 4, 9, 13 and 15 (highlighted lines) were suffering from SAS induced/aggravated by VNS.   
CLBZ : clobazam, ,  CLZ : clozapine,   LTG : lamotrigine, LEV : levetiracetam,  FBM : felbamate OXC : oxcarbazepine, , PER : 
perampanel PB : phenobarbital,  PHT : phenytoin , PGB : pregabaline, RTG : retigabine,, RUF : rufinamide, VPA : valproic 
acid ,ZNS : zonisamide 
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Table 2: diagnosis and treatment of Sleep Apnea Syndrome in all patients 
 Sleep study before VNS 
implantation 
AHI Sleep study after VNS 
implantation  
AHI Treatment 
1. PG 0.4/h PG (twice)* 12.7/h – 0/h Change of parameters 
2. PG 0.4/h PSG 0.4/h  
3. PSG 2/h - -  
4. PG 1.5/h PG 13.5/h None 
5. PG 1.6/h PG 3.8/h  
6. PG 9.5/h PG** 3.6/h Positional  
7. PG 0.4/h PSG 0.8/h  
8. PG 2.9/h PG 2.9/h  
9. PG 17.7/h PG 68/h cPAP 
10. PG 0.5/h PG 0.9/h  
11. PG 0.1/h PG 0/h  
12. PG 3.7/h PSG 3.4/h  
13. PSG 1.1/h PG 45.5/h Change of parameters 
14. PG 0.8/h - -  
15. PG 3.8/h PG 11.1/h Change of parameters 
16. PG 0.8/h PG 1.2/h  
17. PG 0.8/h PG 0.1/h  
18. PSG 2.2/h PG 1.8/h  
Patients 1, 4, 9, 13, 15 were diagnosed and treated for a VNS-induced SAS. 
PSG: polysomnography; PG: ambulatory polygraphy; AHI: apnea-hypopnea index  
* Patient 1 underwent 2 PG after the VNS implantation, the first with standard stimulation and the second with low intensity. 
** Patient 6 underwent the second PG under positional treatment 
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Table 3: characteristics of patients stratified for VNS induced/aggravated SAS  
 
Characteristics 
 Patients with SAS  
(n=5) 
Patients without SAS 
(n=13) 
 
p-value 
Gender Female 
Male 
3 
2 
4 
9 
0.326 * 
Age (median ; range)  31 ; 26-50 31 ; 22-52 1 ** 
BMI Overweight 
 
1 
 
2 
 
1* 
Diabetes or 
hypertension 
 0 0 1* 
Epilepsy type Focal 
Generalized 
4 
1 
7 
6 
0.595* 
Seizures frequency 
(median ; range) 
Baseline Focal (per 
month) 
100 ; 1-300 13 ; 0-75 0.258 ** 
 Baseline 
generalized (per 
year) 
0 ; 0-36 0 ;  0-48 0.960** 
 Effect of VNS on 
seizures  
Decrease of >75% ; 50-90% Decrease of  >70% ; 0-90% 0.459 ** 
VPA medication at 
implant 
VPA 
 
0 
 
7 
 
0.101* 
Parameters of VNS 
device (at time of the 
sleep study) (median ; 
range) 
Intensity  2.0 mA ; 1.75-2.5 mA  1.75 mA ; 0.5-2.25 mA  0.055 ** 
Frequency  20 Hz ; 20-30 Hz  20 Hz ; 20-30 Hz  0.920** 
Pulse duration  250 μs ; 250-250 μs 250 μs ; 250-250 μs 0.960 ** 
Time ON  30 s ; 7-30 s 30 s ; 30-30 s 0.219 ** 
Time OFF  1.8 mn ; 0-3-5 mn 5 mn ; 0.8-5 mn 0.139 ** 
Magnet effect Yes  
No 
3 
2 
9 
4 
1* 
Vigilance Better 
Unchanged  
4 
1 
11 
2 
1* 
SAS : sleep apnea syndrome, VNS : vagus nerve stimulation, VPA : valproic acid, BMI : body mass index 
*Fisher’s exact test, **Mann-Whitney U-test 
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